Answers are grounded in this paper and cite their sources.
Activation of the alternative complement pathway has emerged as a key driver of IgA Nephropathy (IgAN) presentation and outcome, particularly in crescentic forms. Iptacopan, a selective oral factor B inhibitor, has shown promising antiproteinuric effects in clinical trials. We report two monozygotic twins who developed crescentic IgAN at the same age but with markedly divergent clinical courses. Twin A rapidly progressed to end-stage kidney disease (ESKD) despite intensive immunosuppression and later developed recurrent IgAN in a kidney allograft. Twin B, diagnosed through family screening, showed progressive native-kidney disease despite multiple immunosuppressive treatments but did not progress to ESKD. Both exhibited histological features of complement-mediated injury. Iptacopan was initiated for recurrent allograft IgAN in Twin A and progressive native-kidney IgAN in Twin B, resulting in marked proteinuria reduction, stabilization or improvement of kidney function, and resolution of microhematuria and active histologic lesions. These cases highlight the heterogeneous expression of IgAN despite identical genetics and underscore the role of complement activation in disease progression. The favorable clinical and histological responses support iptacopan as a promising targeted therapy for complement-driven IgAN, including crescentic and recurrent post-transplant disease.
No takes yet. Share an insight, caveat, or question.
Alabau et al. (2026) studied this question.